

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Withdrawn) A method of preventing or treating at least one symptom of drug-resistant hypercalcemia comprising administering to a patient at least one substance that inhibits the binding between PTHrP and a receptor thereof.
2. (Withdrawn) The method according to claim 1, wherein the drug-resistant hypercalcemia is resistant to a therapeutic agent for hypercalcemia other than said at least one substance that inhibits the binding between PTHrP and a receptor thereof.
3. (Withdrawn) The method according to claim 2, wherein the therapeutic agent for hypercalcemia is chosen from at least one of a bone resorption-inhibiting agent, a calcium excretion-promoting agent, an agent for inhibiting intestinal absorption of calcium, and a loop diuretic.
4. (Withdrawn) The method according to claim 2, wherein the therapeutic agent for hypercalcemia is a bone resorption-inhibiting agent.
5. (Withdrawn) The method according to claim 4, wherein the bone resorption-inhibiting agent is at least one of bisphosphonate or calcitonin.

6. (Withdrawn) The method according to any one of claims 1 or 2, wherein said at least one substance is an antagonist of the PTHrP receptor.

7. (Withdrawn) The method according to any one of claims 1 or 2, wherein said at least one substance is an anti-PTHrP antibody.

8. (Withdrawn) The method according to any one of claims 1 or 2, wherein said at least one substance is a fragment of an anti-PTHrP antibody or a modified form of the fragment.

9. (Withdrawn) The method according to claim 7, wherein the antibody is monoclonal.

10. (Withdrawn) The method according to claim 7, wherein the antibody is chosen from at least one of a human antibody, a humanized antibody, and a chimeric antibody.

11. (Withdrawn) The method according to claim 7, wherein the antibody is in a humanized form.

12. (Withdrawn) The method according to claim 11, wherein the humanized antibody is humanized #23-57-137-1 antibody.

13. (Withdrawn) The method according to any one of claims 1 or 2, wherein the drug-resistant hypercalcemia is caused by cancer.
14. (Withdrawn) The method according to claim 5, wherein said at least one substance is chosen from at least one of
- a) an antagonist of the PTHrP receptor;
 - b) an anti-PTHrP antibody; and
 - c) a fragment of an anti-PTHrP antibody or a modified form of the fragment.
15. (Withdrawn) The method of claim 14, wherein the antibody is chosen from at least one of a human antibody, a humanized antibody, and a chimeric antibody.
16. (Withdrawn) The method according to claim 5, wherein the drug-resistant hypercalcemia is caused by cancer.
17. (Currently Amended) A method of ~~preventing or treating~~ a patient suffering from or susceptible to at least one symptom of drug-resistant hypercalcemia comprising administering to a patient at least one ~~substance~~ anti-PTHrP antibody that inhibits the binding between PTHrP and a receptor thereof.

18. (Currently Amended) The method according to claim 17, wherein the drug-resistant hypercalcemia is resistant to a therapeutic agent for hypercalcemia other than said at least one ~~substance~~ anti-PTHrP antibody that inhibits the binding between PTHrP and a receptor thereof.

19. (Previously Presented) The method according to claim 18, wherein the therapeutic agent for hypercalcemia is chosen from at least one of a bone resorption-inhibiting agent, a calcium excretion-promoting agent, an agent for inhibiting intestinal absorption of calcium, and a loop diuretic.

20. (Previously Presented) The method according to claim 18, wherein the therapeutic agent for hypercalcemia is a bone resorption-inhibiting agent.

21. (Previously Presented) The method according to claim 20, wherein the bone resorption-inhibiting agent is at least one of bisphosphonate or calcitonin.

22. (Currently Amended) The method according to any one of claims 17 or 18, wherein said at least one ~~substance~~ anti-PTHrP antibody is an antagonist of the PTHrP receptor.

23. (Canceled)

24. (Currently Amended) The method according to any one of claims 17 or 18, wherein said at least one ~~substance~~ anti-PTHrP antibody is a fragment of an anti-PTHrP antibody or a modified form of the fragment.

25. (Currently Amended) The method according to claim 23 17, wherein the antibody is monoclonal.

26. (Currently Amended) The method according to claim 23 17, wherein the antibody is chosen from at least one of a human antibody, a humanized antibody, and a chimeric antibody.

27. (Currently Amended) The method according to claim 23 17, wherein the antibody is in a humanized form.

28. (Previously Presented) The method according to claim 27, wherein the humanized antibody is humanized #23-57-137-1 antibody.

29. (Previously Presented) The method according to any one of claims 17 or 18, wherein the drug-resistant hypercalcemia is caused by cancer.

30-31. (Canceled)

32. (Previously Presented) The method according to claim 21, wherein the drug-resistant hypercalcemia is caused by cancer.